Search | Clinical Trials Finder

Conditions: Pseudomonas Aeruginosa, Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Zafer Soultan; Other
Eligibility: 5 Years to 19 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Cystic Fibrosis
Interventions: AZLI 75 mg three times a day (TID), Placebo three times a day (TID); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 40
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more

Conditions: Non-Cystic Fibrosis Bronchiectasis
Interventions: Ciprofloxacin for Inhalation, Placebo; Drug
Lead sponsor: Aradigm Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 11 more

Conditions: Pulmonary Infections, Pseudomonas Aeruginosa in Cystic Fibrosis
Interventions: TBM100; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Little Rock, Arkansas • Denver, Colorado • Jacksonville, Florida + 16 more

Conditions: Intestinal Multi-drug Resistant Organism Colonization
Interventions: Microbiome Therapeutic, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Cystic Fibrosis, Infections
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Denver, Colorado • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more

Conditions: Non-Small Cell Lung Cancer, Adenocarcinoma
Interventions: SS1 (dsFv) PE38, Paclitaxel, Carboplatin, Bevacizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Participants, Non-cystic Fibrosis Bronchiectasis
Interventions: Rev-56 for Inhalation, Placebo: Normal saline; Combination Product · Drug
Lead sponsor: Revagenix, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
Interventions: meropenem; Drug
Lead sponsor: Joseph Kuti; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Hartford, Connecticut • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 6 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pseudomonas Infection
Interventions: Ciprofloxacin (Cipro, BAYQ3939); Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Cystic Fibrosis
Interventions: Piperacillin-tazobactam combination product; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 8 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Bacterial Pneumonia
Interventions: IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h, Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage., tobramycin nebulization; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 8
States / cities: San Mateo, California • Gainesville, Florida • Atlanta, Georgia + 5 more

Conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
Interventions: IM JZP-458, IV JZP-458; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 67
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Cystic Fibrosis
Interventions: Inhaled AR-501, Inhaled Placebo; Drug
Lead sponsor: Aridis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more

Conditions: Carbapenem-Resistant Enterobacteriaceae
Interventions: Rectal swab collection; Device
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Indianapolis, Indiana • Detroit, Michigan

Conditions: Persistent Infection, Cystic Fibrosis
Interventions: CMTX-101, Placebo; Drug
Lead sponsor: Clarametyx Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more

Conditions: Cystic Fibrosis
Interventions: AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more

Conditions: Cystic Fibrosis
Interventions: Standard Dose YPT-01, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Gram-negative Bacteremia
Interventions: Intravenous Antibiotics, Oral Antibiotics; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more

Conditions: Bacteremia
Interventions: Not listed
Lead sponsor: T2 Biosystems; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Cystic Fibrosis
Interventions: Gallium nitrate, Normal Saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more

Conditions: Leukemia, Hairy Cell
Interventions: Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Miami, Florida + 6 more

Conditions: Pseudomonas Infection
Interventions: Fosfomycin tromethamine, Fosfomycin disodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

Further MT for Antibiotic-Resistant Bacterial Colonization

Remote Sputum Collection in Cystic Fibrosis

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples.

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects